Optimal Timing of BR55 CEUS of the Ovaries

Ovarian Cancer Clinical Trial

Official title:

An Exploratory Study to Determine the Optimal Timing of BR55 Contrast Enhanced Ultrasound (CEUS) of the Ovaries in Pre-menopausal Women

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04248153
• Other study ID #: BR55-109
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 14, 2019
• Est. completion date: March 31, 2024

Study information

• Verified date: August 2023
• Source: Bracco Diagnostics, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an exploratory, single center, open label, prospective study of BR55 to determine the optimal phase of the menstrual cycle for performing BR55 CEUS of the target ovary in premenopausal women scheduled to undergo preventative surgery because of high familial/hereditary or genetic risk for ovarian cancer.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 3
• Est. completion date: March 31, 2024
• Est. primary completion date: October 31, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria: Enroll a subject in this study if the subject meets the following inclusion criteria:

• Is a female subject of at least 18 years of age;

• Is premenopausal;

• Is scheduled to undergo preventative salpingo-oophorectomy for high risk of ovarian cancer not earlier than 24 hours and not later than 5 days following the second BR55 CEUS examination;

• Provides written Informed Consent and is willing to comply with protocol requirements.

Exclusion Criteria: Exclude a subject from this study if the subject does not fulfill the inclusion criteria, or if any of the following conditions are observed:

• Is a pregnant or lactating female. Exclude the possibility of pregnancy:

• by testing on site at the institution (serum ßHCG) within 24 hours prior to the start of investigational product administration,

• by surgical history (e.g., tubal ligation or hysterectomy),

• Has undergone prior systemic therapy for ovarian cancer;

• Has history of concurrent malignancy;

• Has history of any clinically unstable cardiac condition including class III/IV congestive heart failure;

• Has had any severe cardiac rhythm disorders within 7 days prior to enrolment;

• Has severe pulmonary hypertension (pulmonary artery pressure >90mmHg) or uncontrolled systemic hypertension and/or respiratory distress syndrome;

• Has open and/or non-healing wounds in the chest, abdomen and pelvis;

• Has other systemic vascular abnormalities associated with neovascularization that in the opinion of the investigator could significantly affect the ability to evaluate the effects of BR55;

• Is participating in a clinical trial or has participated in another trial with an investigational compound within the past 30 days prior to enrolment;

• Has previously been enrolled in and completed this study;

• Has any known allergy to one or more of the ingredients of the Investigational Product or to any other contrast media;

• Is determined by the Investigator that the subject is clinically unsuitable for the study;

• Has had major surgery, including laparoscopic surgery, within 3 months prior to enrolment;

• Has history of surgery to the ovaries or pelvic inflammatory disease.

Related Conditions & MeSH terms

• Ovarian Cancer

Intervention

Drug:
• BR55
BR55 will be administered at doses of 0.03 mL/kg or 0.05 mL/kg

Locations

Country	Name	City	State
United States	Stanford University Medical Center	Palo Alto	California

Sponsors (2)

Lead Sponsor	Collaborator
Bracco Diagnostics, Inc	National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual assessment of enhancement	BR55-enhanced images will be visually assessed using a 3-point scale (no enhancement, weak enhancement, strong enhancement).	1 day
Primary	Adverse Events	Number of participants who received the contrast agent and experienced an adverse event.	from the time of signing Informed Consent through 24 hrs post dose follow up evaluation